From elder care and telemedicine to neutraceuticals and more, Novo offers a broad range of solutions
Imagine being able to diversify your holdings in the health-care market with just one stock. Actually, you don’t have to imagine it because this goal is achievable right now with Novo Integrated Sciences, Inc. (NVOS).
Not only that, but you’ll get immediate exposure to top-of-the-line medical-care technology with a position in NVOS stock, at a highly affordable price point.
Ultimately, Novo Integrated Sciences is pioneering a holistic approach to patient-first health and wellness. The company is meeting and exceeding this objective through a multidisciplinary health-care ecosystem of services and product innovation.
This is the type of asset which you can just buy and hold for years, as the health-care industry is bound to grow over time and Novo’s multifaceted business model is designed to grow along with the market.
A Closer Look at NVOS Stock
I’m glad that you’re reading this article today, as you’ve found the perfect entry point for a long-term position in NVOS stock.
Just in the past month, the stock has spiked above $1.50 multiple times. NVOS stock has also bounced off of $1.30 many times, so it appears that there are buyers ready to swoop in when the stock gets to that price point.
The stock happens to be $1.30 as I’m writing this, so hopefully you’ll already have a self-directed broker and be ready to make a move.
And by the way, NVOS stock has reached $2 and higher, so the possibility of a 2x move or even more is entirely possible.
An Essential Patent
Among the most important components of Novo’s business is the company’s patented NHP 2.0 platform and proprietary production process.
For instance, the NHP 2.0 platform enables the company to implement its Advanced Nutraceutical Manufacturing segment with unique, proprietary manufacturing capabilities. Through this platform, Novo is able to preserve product efficacy from batch to batch and bring nutraceuticals into line with the rigors of pharmaceutical grade manufacturing.
Here’s how it works. With NHP 2.0, Novo develops specialty ingredients and formulations, creates a biological signature of ingredients, and examines drug-to-drug interactions, thereby lowering the risk and cost of clinical trials. In other words, Novo can take the ingredients, research and define them, and optimize the composition to provide an improved formula and an end product with reproducible efficacy.
As you can see, Novo is truly committed to advancing breakthrough science. The company even has a subsidiary, known as acenzia, that’s dedicated to providing personalized diagnostics and identifying innovative therapeutics specific to particular ailments.
What really sets acenzia apart from its competitors is its robust science platform. To that end, the company has dedicated a large percentage of it 36,000 square foot lab to world-class R&D laboratories with unique capabilities to handle complex chemical combinations and biologics.
A Game Changer in Telehealth
Telemedicine, also known as telehealth, is a rapidly growing market in the wake of Covid-19.
On April 1, 2020, the Novo Family launched the Novo Telemedicine Platform, through which a number of multidisciplinary primary health care clinicians have been providing low-cost virtual contact with elder-care clients for physiotherapy sessions, non-critical resident reviews, and exercise-related activity.
Novo is fully prepared to continue the company’s efforts to develop and expand the Novo Telemedicine Platform.
As evidence of this commitment, Novo’s wholly owned subsidiary, Novo Healthnet Limited, and EK-Tech Solutions Inc. have established a joint venture company, MiTelemed+ Inc., to operate, support, and expand access and functionality of EK-Tech’s enhanced proprietary Telehealth platform, known as iTelemed.
MiTelemed+, through the iTelemed platform, allows Novo to offer the patient and the practitioner a sophisticated and enhanced telehealth interaction.
Through the interface of sophisticated peripheral based diagnostic tools operated by skilled support workers in the patient’s remote location, the practitioner’s ability and comfort to provide a uniquely comprehensive evaluation, diagnosis, and treatment solution is dramatically elevated.
Plus, the iTelemed platform will interface with Novo’s mobile application, NovoConnect, to provide patients and practitioners with an additional platform to administer patients remotely and create virtual visits that are intended to be as real and as effective as a physical visit.
The Bottom Line
Both the company’s patented NHP 2.0 platform and its MiTelemed+ innovation could be transformative to modern health care as we know it.
At the same time, NVOS stock is cheap and easily available, as there’s plenty of trading volume on this stock.
Therefore, don’t hesitate to broaden and diversify your health-care portfolio today with a long-term position in NVOS stock.
